Pulmonary Hypertension & Lung Disease

Trial Objective

Pulmonary Hypertension & Lung DiseaseThe purpose of this clinical trial is to determine the safety and effectiveness of an inhaled investigational medication, Treprostinil, in treating pulmonary hypertension related to Interstitial Lung Disease (ILD), including Combined Pulmonary Fibrosis and Emphysema (CPFE).


This trial is active and currently recruiting.

Who Can Participate

Individuals with pulmonary hypertension related to interstitial lung disease (ILD), including combined pulmonary fibrosis and emphysema (CPFE).

Age: 18+    Gender: Any Gender

Estimated Time Commitment

7 visits over 20 weeks



Trial Contact

For more information, contact:

Kris Eliopoulos

Kris Eliopoulos

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

United Therapeutics Corporation

Principal Investigators

Request More Information